174 related articles for article (PubMed ID: 32750229)
1. Increased curative treatment is associated with decreased prostate cancer-specific and overall mortality in senior adults with high-risk prostate cancer; results from a national registry-based cohort study.
Aas K; Dorothea Fosså S; Åge Myklebust T; Møller B; Kvåle R; Vlatkovic L; Berge V
Cancer Med; 2020 Sep; 9(18):6646-6657. PubMed ID: 32750229
[TBL] [Abstract][Full Text] [Related]
2. Comparative Survival Outcomes of High-risk Prostate Cancer Treated with Radical Prostatectomy or Definitive Radiotherapy Regimens.
Aas K; Berge V; Myklebust TÅ; Fosså SD
Eur Urol Open Sci; 2021 Apr; 26():55-63. PubMed ID: 34337508
[TBL] [Abstract][Full Text] [Related]
3. Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
Heering M; Berg KD; Brasso K; Iversen P; Røder MA
Surg Oncol; 2017 Mar; 26(1):21-27. PubMed ID: 28317581
[TBL] [Abstract][Full Text] [Related]
4. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
5. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
6. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study.
Matthes KL; Pestoni G; Korol D; Van Hemelrijck M; Rohrmann S
Urol Oncol; 2018 Jun; 36(6):309.e15-309.e23. PubMed ID: 29576269
[TBL] [Abstract][Full Text] [Related]
7. Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway.
Aas K; Axcrona K; Kvåle R; Møller B; Myklebust TÅ; Axcrona U; Berge V; Fosså SD
Urology; 2017 Dec; 110():140-147. PubMed ID: 28823634
[TBL] [Abstract][Full Text] [Related]
8. Localised prostate cancer in elderly men aged 80-89 years, findings from a population-based registry.
Vatandoust S; Kichenadasse G; O'Callaghan M; Vincent AD; Kopsaftis T; Walsh S; Borg M; Karapetis CS; Moretti K
BJU Int; 2018 May; 121 Suppl 3():48-54. PubMed ID: 29603585
[TBL] [Abstract][Full Text] [Related]
9. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.
Butler SS; Mahal BA; Lamba N; Mossanen M; Martin NE; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2019 Sep; 125(18):3164-3171. PubMed ID: 31150125
[TBL] [Abstract][Full Text] [Related]
10. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
11. 10-Year Mortality After Radical Prostatectomy for Localized Prostate Cancer in the Prostate-specific Antigen Screening Era.
Mendhiratta N; Lee T; Prabhu V; Llukani E; Lepor H
Urology; 2015 Oct; 86(4):783-8. PubMed ID: 26163812
[TBL] [Abstract][Full Text] [Related]
12. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
[TBL] [Abstract][Full Text] [Related]
13. Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.
Tilki D; Chen MH; Wu J; Huland H; Graefen M; Braccioforte M; Moran BJ; D'Amico AV
JAMA Oncol; 2019 Feb; 5(2):213-220. PubMed ID: 30452521
[TBL] [Abstract][Full Text] [Related]
14. Commentary on "initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer." Aizer AA, Chen MH, Hattangadi J, D'Amico AV. Harvard Radiation Oncology program, Boston, MA.: BJU Int 2013. doi: 10.1111/j.1464-410X.2012.11789.x. [Epub ahead of print].
Ritter MA
Urol Oncol; 2014 Feb; 32(2):208-9. PubMed ID: 24445289
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy.
Mossanen M; Nepple KG; Grubb RL; Androile GL; Kallogjeri D; Klein EA; Stephenson AJ; Kibel AS
Eur Urol Oncol; 2018 Jun; 1(2):143-148. PubMed ID: 31100238
[TBL] [Abstract][Full Text] [Related]
16. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.
Pompe RS; Gild P; Karakiewicz PI; Bock LP; Schlomm T; Steuber T; Graefen M; Huland H; Tian Z; Tilki D
Prostate; 2018 Jun; 78(9):676-681. PubMed ID: 29570821
[TBL] [Abstract][Full Text] [Related]
17. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
18. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
[TBL] [Abstract][Full Text] [Related]
19. Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model.
Thurtle DR; Greenberg DC; Lee LS; Huang HH; Pharoah PD; Gnanapragasam VJ
PLoS Med; 2019 Mar; 16(3):e1002758. PubMed ID: 30860997
[TBL] [Abstract][Full Text] [Related]
20. Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer.
Vetterlein MW; Löppenberg B; Karabon P; Dalela D; Jindal T; Sood A; Chun FK; Trinh QD; Menon M; Abdollah F
Cancer; 2017 Sep; 123(17):3241-3252. PubMed ID: 28472547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
